N. Schlesinger

Publications198
h-index38
Citations4,646
Highly Influential Citations130
Claim Author Page
Author pages are created from data sourced from our academic publisher partnerships and public sources.

Recommended Authors

  • N. Dalbeth
  • 663 Publications • 19,217 Citations
  • H. Schumacher
  • 664 Publications • 27,761 Citations
  • Hyon K. Choi
  • 429 Publications • 44,155 Citations
  • J. Singh
  • 790 Publications • 113,893 Citations
  • Publications
  • Influence
Diagnosis of gout by ultrasound.
TLDR
US can detect deposition of MSU crystals on cartilaginous surfaces (P < 0.001) as well as tophaceous material and typical erosions, and may serve as a non-invasive means to diagnose gout.
View on PubMed
Canakinumab for the treatment of acute flares in difficult-to-treat gouty arthritis: Results of a multicenter, phase II, dose-ranging study.
TLDR
It is indicated that canakinumab 150 mg provides rapid and sustained pain relief in patients with acute gouty arthritis, and significantly reduces the risk of recurrent flares compared with triamcinolone acetonide.
View on PubMed
Canakinumab for acute gouty arthritis in patients with limited treatment options: results from two randomised, multicentre, active-controlled, double-blind trials and their initial extensions
TLDR
Canakinumab provided significant pain and inflammation relief and reduced the risk of new flares in these patients with acute gouty arthritis.
View on BMJ
Diagnosis of gout: clinical, laboratory, and radiologic findings.
  • N. Schlesinger
  • Medicine
    The American journal of managed care
  • 15 November 2005
TLDR
An overview of the various classification criteria, clinical presentations, and laboratory and radiologic studies needed to make the diagnosis of gout is presented.
View on PubMed
Canakinumab reduces the risk of acute gouty arthritis flares during initiation of allopurinol treatment: results of a double-blind, randomised study
TLDR
Single canakinumab doses ≥50 mg or four 4-weekly doses provided superior prophylaxis against flares compared with daily colchicine 0.5 mg at 16 weeks.
View on BMJ
Uric acid in Parkinson's disease
TLDR
It is possible that a high purine diet in patients with PD may slow progression of the disease and the manipulation of SU levels holds promise in the treatment of PD.
View on Wiley
Management of acute and chronic gouty arthritis: present state-of-the-art.
TLDR
The use of recombinant urate oxidase in patients with chronic gout is limited by the need for parenteral administration, the potential antigenicity and production of anti-urate oxidase antibodies, and declining efficacy.
View on PubMed
Local ice therapy during bouts of acute gouty arthritis.
TLDR
Cold applications may be a useful adjunct to treatment of acute gouty arthritis and due to the small sample size the authors could not show statistically significant improvement in all the variables that tended to suggest that effect was more than simply analgesic.
View on PubMed
Ultrasonography shows disappearance of monosodium urate crystal deposition on hyaline cartilage after sustained normouricemia is achieved
TLDR
In patients with monosodium urate crystal proven gout, sonographic signs of deposition of MSU crystals on the surface of hyaline cartilage disappeared completely if sustained normouricemia was achieved, the first report showing that characteristic sonographic changes are influenced by ULDs once SU levels remain ≤6 mg/dl for 7 months or more.
View on Springer
Colchicine to Weather the Cytokine Storm in Hospitalized Patients with COVID-19
TLDR
Patients receiving colchicine were approximately five times more likely to be discharged than those receiving standard of care at the end of the 28 day follow-up, and these observations warrant further investigation in large controlled clinical trials.
View PDF
...
...